Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29847105 | 1.00 | GPR35 (0.46) | GPR35ALDH1A1MAPK1HPGDTP53 | |
| SCHEMBL6997080 | 0.98 | GPR35 (0.44) | GPR35ALDH1A1MAPK1HPGDTP53 | |
| SCHEMBL6999559 | 0.98 | GPR35 (0.44) | GPR35ALDH1A1MAPK1HPGDTP53 | |
| SCHEMBL1647316 | 0.96 | GPR35 (0.46) | GPR35ALDH1A1MAPK1HPGDTP53 | |
| SCHEMBL9452619 | 0.85 | MAPT (0.41) | GPR35ALDH1A1MAPK1HPGDTP53 | |
| SCHEMBL14411992 | 0.80 | SIRT6 (0.43) | GPR35ALDH1A1MAPK1HPGDTP53 | |
| SCHEMBL9331116 | 0.80 | MAPT (0.54) | GPR35ALDH1A1MAPK1HPGDTP53 | |
| SCHEMBL24869958 | 0.79 | PNMT (0.54) | GPR35ALDH1A1MAPK1HPGDTP53 | |
| SCHEMBL28069542 | 0.79 | PNMT (0.54) | GPR35ALDH1A1MAPK1HPGDTP53 | |
| Hydrochloric Acid SCHEMBL9331794 | 0.79 | MAPT (0.52) | GPR35ALDH1A1MAPK1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115038707-A | Azepine condensed ring compound and medical application thereof | 中国医药研究开发中心有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-8093244-B2 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2330105-A1 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS Corporation (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1869020-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl | ICOS Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1765808-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006105262-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl | ICOS CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006012308-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1015437-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AG (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| EP-1015437-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999012915-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-03-18 | — | — | WO | disclosed |
| EP-0070531-B1 | TETRAHYDRONAPHTHOXAZOLES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4443610-A | Bicyclothiazoles | USV PHARMACEUTICAL CORPORATION (US) | 1984-04-17 | — | — | US | disclosed |
| US-4440935-A | Bicycloimidazoles | USV PHARMACEUTICAL CORPORATION (US) | 1984-04-03 | — | — | US | disclosed |
| EP-0070531-A2 | Tetrahydronaphthoxazoles | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1983-01-26 | — | — | EP | disclosed |
| US-4368201-A | Tetrahydronaphthoxazoles | USV PHARMACEUTICAL CORPORATION (US) | 1983-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | CHEK1, CHEK2, PCNA | GPR35 4118/4885ALDH1A1 3398/4885MAPK1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.